Kazia: Up as interim cancer study analysis shows consistency with prior data

Kazia Therapeutics

18/11/2020 13:51

** U.S.-listed shares of cancer-focused biotech firm
 KZIA.O  rise 14.2% to $11.28 premarket; stock set for over
five-year high
    ** KZIA said on Tuesday new interim analysis of mid-stage
study of its drug candidate paxalisib to treat glioblastoma is
highly consistent with prior safety and efficacy data
 urn:newsml:reuters.com:*:nPNA8QBQka
    ** Glioblastoma is an aggressive type of cancer that can
occur in brain or spinal cord
    ** Co expects study to conclude in H1 2021 but says it has
already provided useful information to guide development of
paxalisib
    ** KZIA says it has moved into operational phase of its
pivotal glioblastoma study , which is likely to be its primary
focus
    ** Up to Tuesday's close, stock had more than doubled this
year

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))